Cargando…

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3

With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations,...

Descripción completa

Detalles Bibliográficos
Autores principales:	de la Fouchardière, Christelle, Gamradt, Pia, Chabaud, Sylvie, Raddaz, Maxime, Blanc, Ellen, Msika, Olivier, Treilleux, Isabelle, Bachy, Sophie, Cattey-Javouhey, Anne, Guibert, Pierre, Sarabi, Matthieu, Rochefort, Pauline, Funk-Debleds, Pamela, Coutzac, Clélia, Ray-Coquard, Isabelle, Peyrat, Patrice, Meeus, Pierre, Rivoire, Michel, Dupré, Aurélien, Hennino, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/ https://www.ncbi.nlm.nih.gov/pubmed/35455739 http://dx.doi.org/10.3390/jpm12040623

Ejemplares similares

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
por: Derbel, Olfa, et al.
Publicado: (2013)

Stromal Protein-Mediated Immune Regulation in Digestive Cancers
por: Gamradt, Pia, et al.
Publicado: (2021)

New developments in treatment of ovarian carcinoma: focus on trabectedin
por: Cassier, Philippe A, et al.
Publicado: (2010)

βig-h3-structured collagen alters macrophage phenotype and function in pancreatic cancer
por: Bachy, Sophie, et al.
Publicado: (2022)

Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
por: Hodroj, Khalil, et al.
Publicado: (2021)

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
por: Levard, Alice, et al.
Publicado: (2013)

Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial
por: Dupré, Aurélien, et al.
Publicado: (2017)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pericyte stem cells induce Ly6G (+) cell accumulation and immunotherapy resistance in pancreatic cancer
por: Wu, Zhichong, et al.
Publicado: (2023)

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
por: Heudel, P., et al.
Publicado: (2021)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value
por: Jiang, Xiaojun, et al.
Publicado: (2015)

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012)

Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine
por: Frappart, Pierre-Olivier, et al.
Publicado: (2020)

Angiogenesis Associated With Visceral and Subcutaneous Adipose Tissue in Severe Human Obesity
por: Ledoux, Séverine, et al.
Publicado: (2008)

Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting
por: Asvatourian, Vahé, et al.
Publicado: (2018)

Molecular Tuning of Filamin A Activities in the Context of Adhesion and Migration
por: Lamsoul, Isabelle, et al.
Publicado: (2020)

Combatting PDAC with two tumor-targeting small RNAs
por: Kasinski, Andrea L.
Publicado: (2019)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021)

Loss of FGFR4 promotes the malignant phenotype of PDAC
por: D’Agosto, Sabrina, et al.
Publicado: (2022)

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group
por: Mourksi, Nour‐El‐Houda, et al.
Publicado: (2022)

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer
por: Cohen, Romain, et al.
Publicado: (2021)

Very long‐term survivors among patients with metastatic soft tissue sarcoma
por: Carbonnaux, Mélodie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vhesi8i0bu9nk40rn8ki3j8k28